Evidence map›Paper›PMID 38009551›Full record

ArticleAddiction (Abingdon, England)2024

Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial.

Jonathan B Bricker, Margarita Santiago-Torres, Kristin E Mull, Brianna M Sullivan, Sean P David, Joy Schmitz, Angela Stotts, Nancy A Rigotti

Abstract read
In one paragraph

Article in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan B BrickerDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-5694-8795
Margarita Santiago-TorresDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0001-6051-3172
Kristin E MullDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID 0000-0002-7918-3078
Brianna M SullivanDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Sean P DavidUniversity of Chicago Pritzker School of Medicine, NorthShore University Health System, Chicago, IL, USA.
Joy SchmitzDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.
Angela StottsDepartment of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA.
Nancy A RigottiTobacco Research and Treatment Center, Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Funding

Full Scale Randomized Trial of an Innovative Conversational Agent for Smoking CessationR01CA247156 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRICKER, JONATHAN B · 2020 to 2024
$3.6M
Quit2Heal: Rigorous Randomized Trial of a Smartphone Application to Help Cancer Patients Stop SmokingR01CA253975 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRICKER, JONATHAN B · 2020 to 2024
$3.5M
Randomized Trial of an Innovative Smartphone Intervention for Smoking CessationR01CA192849 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRICKER, JONATHAN B · 2015 to 2019
$3.1M
NCI NIH HHS R01 CA192849NCI NIH HHS R01CA192849NCI NIH HHS R01 CA247156NCI NIH HHS R01 CA253975
6 · The paper itself

Abstract

BACKGROUND AND

aimsiCanQuit is a smartphone application (app) proven efficacious for smoking cessation in a Phase III randomized controlled trial (RCT). This study aimed to measure whether medications approved by the US Food and Drug Administration (FDA) for smoking cessation would further enhance the efficacy of iCanQuit, relative to its parent trial comparator-the National Cancer Institute's (NCI's) QuitGuide app.

designSecondary analysis of the entire parent trial sample of a two-group (iCanQuit and QuitGuide), stratified, doubled-blind RCT.

settingUnited States.

participantsParticipants who reported using an FDA-approved cessation medication on their own (n = 619) and those who reported no use of cessation medications (n = 1469).

interventionsParticipants were randomized to receive iCanQuit app or NCI's QuitGuide app. MEASUREMENTS: Use of FDA-approved medications was measured at 3 months post-randomization. Smoking cessation outcomes were measured at 3, 6 and 12 months. The primary outcome was 12-month self-reported 30-day point prevalence abstinence (PPA).

findingsThe data retention rate at the 12-month follow-up was 94.0%. Participants were aged 38.5 years, 71.0% female, 36.6% minority race/ethnicity, 40.6% high school or less education, residing in all 50 US States and smoking 19.2 cigarettes/day. The 29.6% of all participants who used medications were more likely to choose nicotine replacement therapy (NRT; 78.8%) than other cessation medications (i.e. varenicline or bupropion; 18.3 and 10.5%, respectively) and use did not differ by app treatment assignment (all P > 0.05). There was a significant (P = 0.049) interaction between medication use and app treatment assignment on PPA. Specifically, 12-month quit rates were 34% for iCanQuit versus 20% for QuitGuide [odds ratio (OR) = 2.36, 95% confidence interval (CI) = 1.59, 3.49] among participants reporting any medication use, whereas among participants reporting no medication use, quit rates were 28% for iCanQuit versus 22% for QuitGuide (OR = 1.41, 95% CI = 1.09, 1.82). Results were stronger for those using only NRT: 40% quit rates for iCanQuit versus 18% quit rates for QuitGuide (OR = 3.57, 95% CI = 2.20, 5.79).

conclusionsThe iCanQuit smartphone app for smoking cessation was more efficacious than the QuitGuide smartphone app, regardless of whether participants used medications to aid cessation. Smoking cessation medications, especially nicotine replacement therapy, might enhance the efficacy of the iCanQuit app.

Indexed as

Mobile ApplicationsSmoking CessationAdultBupropionClinical Trials, Phase III as TopicFemaleHumansMaleRandomized Controlled Trials as TopicTobacco Use Cessation DevicesVareniclineBupropionVareniclineAcceptance and commitment therapyACTdigital interventionsiCanQuitnicotine replacement therapypharmacotherapysmartphone applicationssmoking cessation

Identifiers

PMID38009551
PMCPMC10932808

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.